Suppr超能文献

用于治疗肥胖症的单次给药自增强微针贴剂。

Single-Administration Self-Boosting Microneedle Patch for The Treatment of Obesity.

作者信息

Singh Parbeen, Vinikoor Tra, Sharma Nidhi, Nelson Nicole, Prasadh Somasundaram, Oiknine Ralph, Nguyen Thanh Duc

机构信息

Department of Mechanical Engineering, University of Connecticut, United States.

Department of Biomedical Engineering, University of Connecticut, Storrs, CT 06269, USA.

出版信息

Adv Ther (Weinh). 2024 Sep;7(9). doi: 10.1002/adtp.202400028. Epub 2024 May 21.

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are one of the most effective treatments for obesity. The current therapy associated with repeated subcutaneous injections to maintain the drug therapeutic effect causes patient compliance issues and raises environmental concerns (due to sharp biohazard waste from disposed syringes/needles). Herein, we report a programmable scheduled release microneedles (PSR-MNs) system for delivering Semaglutide (a GLP-1 RA agent with a half-life of ~ 7 days) to manage and treat obesity. A single skin administration of a PSR-MNs patch (2 cm × 2 cm) which contains 4 programmable core-shell MNs patches (1 cm each, so-called pixels) enables the repeated release of Semaglutide every 7 days and sustains the drug efficacy for an unprecedented one-month period, simulating the effect of using four bolus injections spaced 7 days apart. Our PSR-MNs system provides an advanced injection-free platform to significantly enhance the current treatment of obesity with GLP-1RAs, addressing concerns related to pain, needle phobia, high cost and the need of medical facilities/personnel in traditional injections to administer the drug.

摘要

胰高血糖素样肽-1受体激动剂(GLP-1 RAs)是治疗肥胖症最有效的方法之一。目前的治疗方法需要反复皮下注射以维持药物治疗效果,这会导致患者依从性问题,并引发环境问题(由于废弃注射器/针头产生的尖锐生物危害废物)。在此,我们报告了一种用于递送司美格鲁肽(一种半衰期约为7天的GLP-1 RA药物)以管理和治疗肥胖症的可编程定时释放微针(PSR-MNs)系统。单次经皮给予一个包含4个可编程核壳微针贴片(每个1厘米,即所谓的像素)的PSR-MNs贴片(2厘米×2厘米),能够每7天重复释放司美格鲁肽,并在长达一个月的时间内维持药物疗效,模拟了每7天进行一次四次推注注射的效果。我们的PSR-MNs系统提供了一个先进的无针平台,可显著改善目前使用GLP-1 RAs治疗肥胖症的方法,解决与疼痛、针头恐惧症、高成本以及传统注射给药所需的医疗设施/人员相关的问题。

相似文献

9
Laser therapy for retinopathy in sickle cell disease.激光疗法治疗镰状细胞病视网膜病变。
Cochrane Database Syst Rev. 2022 Dec 12;12(12):CD010790. doi: 10.1002/14651858.CD010790.pub3.

本文引用的文献

8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验